Current ENABLE-2 projects
ENABLE-2 is currently supporting four promising projects in the pursuit of new antibiotics: One each from biotech companies QureTech Bio AB and Thioredoxin Systems AB and two projects from Uppsala University.
PROJECT GmPcides
A new class of antibacterial compounds against gram-positive bacteria & a well-developed chemistry platform to improve these new compounds
Resident at QureTech Bio AB, Umeå
Fredrik Almqvist, Research Director
QureTech Bio AB
Fredrik.Almqvist@umu.se
Helén Fält, CEO
QureTech Bio AB
Helen.Falt@quretech.com
PROJECT QuinGiT
A novel chemical class with promising properties for continued development
Resident at Preparative Medicinal Chemistry, Dep of Medicinal Chemistry, Uppsala University
Luke Odell, Professor
Uppsala University
Luke.Odell@ilk.uu.se
PROJECT JEDI
A novel target with no preexisting resistance and a new compound class showing very good efficacy in animal models
Resident at Drug Design and Discovery, Dep of Medicinal Chemistry & Dep of Medical Biochemistry and Microbiology, Uppsala University
Diarmaid Hughes, Professor
Uppsala University
Diarmaid.Hughes@imbim.uu.se
Anders Karlén, Professor
Uppsala University
Anders.Karlen@ilk.uu.se
PROJECT EbsArgent
A novel class of antibiotic active against multidrug-resistant gram-positive as well as gram-negative bacteria
Resident at Thioredoxin Systems AB, Solna
Elias Arnér, MD PhD, Board Member, Scientific Advisor
Thioredoxin Systems AB
+46 70 556 96 94, ea@txnsystems.com
Mohamad Takwa, PhD, Board Member, CEO
Thioredoxin Systems AB
+46 72-322 22 21, mt@txnsystems.com
CONTACT
Susanna Thörnqvist, Project Coordinator
Uppsala University
Susanna.Thornqvist@ilk.uu.se